CI Bio-Revolution Idx ETF (CDNA.TO)
15.12
-0.11
(-0.72%)
CAD |
TSX |
Apr 25, 16:00
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.44% | -1.18% | 4.590M | 325.00 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| 0.59% | 43.01% | 0.00 | Upgrade |
Basic Info
| Investment Strategy | |
| CDNA seeks to replicate, to the extent reasonably possible, the performance of a global biotechnology and genomics industry index, net of expenses. Currently, CDNA seeks to replicate the performance of the Solactive Global Genomics Immunology and Medical Revolution CAD Hedged Index NTR (the “Index”). The Index intends to track the performance of companies that have business operations in the global biotechnology and genomics industry using the ARTIS® classification system. The Index hedges foreign currency exposure back to Canadian dollars. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | Morningstar Gbl GR CAD |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | -- |
| Fund Owner Firm Name | CI Investments Inc |
| Prospectus Benchmark Index | |
| Sol Gbl Gen Immu & Med Revltn NR Hdg CAD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Lijon Geeverghese | 2.10 yrs |
Performance Versus Category
As of April 25, 2024. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of April 25, 2024.
Basic Info
| Investment Strategy | |
| CDNA seeks to replicate, to the extent reasonably possible, the performance of a global biotechnology and genomics industry index, net of expenses. Currently, CDNA seeks to replicate the performance of the Solactive Global Genomics Immunology and Medical Revolution CAD Hedged Index NTR (the “Index”). The Index intends to track the performance of companies that have business operations in the global biotechnology and genomics industry using the ARTIS® classification system. The Index hedges foreign currency exposure back to Canadian dollars. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | Morningstar Gbl GR CAD |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | -- |
| Fund Owner Firm Name | CI Investments Inc |
| Prospectus Benchmark Index | |
| Sol Gbl Gen Immu & Med Revltn NR Hdg CAD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Lijon Geeverghese | 2.10 yrs |